Sab BiotherapeuticsSABS
13F holders, Q2 2024 (June 30)22holders −2
2new positions
4sold out
1famous investor
$3.10avg. 13F price*
At the end of Q2 2024, 22 institutions reported holding Sab Biotherapeutics Inc. (SABS) in their 13F filings, down 2 from Q1 2024. 2 opened new positions and 4 sold out. The largest holders were BVF Inc. ($2.8M), RTW Investments, LP ($2.4M) and Marshall Wace, LLP ($1.4M). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Sab Biotherapeutics Inc.
- CUSIP
- 78397T202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $61K |
| Exits | 4 | $834K |
All 13F filers, Q1 2024 → Q2 2024: 127,935 shares bought and 340,450 shares sold, net −212,515 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 22 holders
| BVF Inc. | 0.08% | No change | 917,826 | $2.8M |
| RTW Investments, LP | 0.04% | Reduce -16.4% | 766,946 | $2.4M |
| Marshall Wace, LLP | 0.00% | No change | 459,168 | $1.4M |
| Sessa Capital IM, L.P. | 0.06% | No change | 458,457 | $1.4M |
| Vanguard Group Inc. | 0.00% | Add +56.7% | 276,336 | $857K |
| Geode Capital Management, LLC | 0.00% | Reduce -6.4% | 59,415 | $184K |
| Millennium Management | 0.00% | Reduce -2.3% | 52,784 | $164K |
| Pathstone Holdings, LLC | 0.00% | No change | 50,650 | $157K |
| First Manhattan Co. Llc. | 0.00% | No change | 24,577 | $76K |
| First PREMIER Bank | 0.02% | New | 19,386 | $60K |
| Institutional & Family Asset Management, LLC | 0.01% | No change | 19,201 | $60K |
| BlackRock Inc. | 0.00% | Add +116.9% | 13,752 | $43K |
| Osaic Holdings, Inc. | 0.00% | Add +0.2% | 4,534 | $14K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +66.6% | 2,393 | $7K |
| Morgan Stanley | 0.00% | Reduce -41.7% | 699 | $2K |
| Princeton Global Asset Management LLC | 0.00% | No change | 500 | $2K |
| GS Investments, Inc. | 0.00% | No change | 200 | $620 |
| Bank of America Corp. | 0.00% | New | 165 | $511 |
| JPMorgan Chase & Co. | 0.00% | Add +1.9% | 106 | $329 |
| Harbour Investments, Inc. | 0.00% | No change | 50 | $155 |
| Qube Research & Technologies Ltd | 0.00% | No change | 6 | $19 |
| Royal Bank of Canada | 0.00% | No change | 6 | $0 |
"% of holder's portfolio" is SABS's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. the manager owns.